| | |
| Clinical data | |
|---|---|
| Other names | CORT108297; ADS-108297; ADS108297 |
| Routes of administration | Oral [1] |
| Drug class | Antiglucocorticoid; Selective glucocorticoid receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H25F4N3O3S |
| Molar mass | 535.56 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CORT-108297, also known as ADS-108297, is a nonsteroidal selective glucocorticoid receptor modulator (SEGRM) with mixed glucocorticoid and antiglucocorticoid actions which is under development for the treatment of Alzheimer's disease, cognition disorders, memory disorders, and post-traumatic stress disorder (PTSD). [1] [2] [3] [4] It was also being developed for treatment of other psychiatric disorders and weight gain, but development for these indications was discontinued. [1] The drug is taken by mouth. [1] As of November 2022, CORT-108297 is in phase 2 clinical trials for the aforementioned active indications. [1] [2]